Trying to Pin a Figure on the Cost of Poor Pharma Quality? For Baxter, Heparin, and Other Quality Issues, Led to 26% Profit Loss

More News:

• 05/22/2013 Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online

  Novo A/S has acquired Xellia Pharmaceuticals of Norway

• 05/22/2013 Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online

  Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan

• 05/22/2013 New Asthma Drug Offers Hope for PatientsFrom Forbes

  An experimental asthma drug could give new hope to patients for whom existing medicines are not enough

• 05/21/2013 Syrian Pharma Production Nearly Halted by WarFrom AFP

  A shortage of foreign currency has brought production to a near halt in Syria

• 05/21/2013 Camfil APC Opens Manufacturing Plant in the UKFrom Camfil

  Camfil announced the grand opening of its new 40,000-sq.-ft. facility

• 05/21/2013 Actavis Acquiring Warner Chilcott for $8.5BFrom AP

  Actavis to buy Warner Chilcott in an all-stock transaction

• 05/17/2013 Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics

  NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration

• 05/16/2013 Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com

  Agreement creates unique strategic collaboration for development and clinical trial execution

• 05/16/2013 $15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com

  Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.

• 05/15/2013 Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems

  Company hosts hands-on demonstrations of its Growth Direct System

• All news »